SCHEMBL4786092

SCHEMBL4786092

Cn1nc(Nc2cccc(Cl)c2)c2cc(C(N)=O)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.52
CSNK2A2 P19784 5/20 0.51
CSNK2B P67870 5/20 0.51
CSNK2A1 P68400 5/20 0.51
PIM1 P11309 4/20 0.51
PIM2 Q9P1W9 3/20 0.51
KDM4C Q9H3R0 1/20 0.46
PARP1 P09874 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ROCK2 O75116 1/20 0.43
PIM3 Q86V86 1/20 0.43
MAPT P10636 3/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4783757 0.90 AKR1C3 (0.51) KDRCSNK2A2CSNK2BCSNK2A1PIM1
SCHEMBL4740878 0.84 EGFR (0.51) KDM4CMEN1KMT2AMAPTHPGD
SCHEMBL4786745 0.81 GAA (0.53) KDRMEN1KMT2AMAPTHPGD
SCHEMBL4740887 0.80 MEN1 (0.56) PIM1KDM4CMEN1KMT2AMAPT
SCHEMBL4785974 0.80 FADS1 (0.55) KDM4CMEN1KMT2AMAPTHPGD
SCHEMBL4810776 0.78 MEN1 (0.43) KDM4CMEN1KMT2AMAPTHPGD
SCHEMBL4739653 0.78 MEN1 (0.45) PIM1KDM4CMEN1KMT2AMAPT
SCHEMBL4742065 0.78 FADS1 (0.59) KDRMEN1KMT2AMAPTHPGD
SCHEMBL4804196 0.77 MAPT (0.44) CSNK2A2CSNK2BCSNK2A1KDM4CMEN1
SCHEMBL4738611 0.76 KDM4C (0.48) KDRKDM4CMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 KDR 1066/4885CSNK2A2 1337/4885CSNK2B 2047/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG KDR 4840/4885CSNK2A2 1683/4885CSNK2B 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.